NIT is led by a highly experienced team of scientists, clinicians and strategists, relentlessly pursuing the development of novel cancer and immune therapies to bring better treatment options to patients.

Se Hwan Yang, Ph.D. – Chief Executive Officer

Dr. Se Hwan Yang founded NeoImmuneTech in January 2014. Dr. Yang has created several intellectual-property protected inventions, including the hyFc® platform technology and Hyleukin-7 drug candidate. Prior to his position at NIT, Dr. Yang was Genexine’s Head of Research Institute and Business division from 2007 to 2014 and has served as a BOD member of Genexine. He received his Ph.D. from Pohang University of Science and Technology and has over 20 years of experiences of research, product development and business in life sciences, including molecular biology, immunology and protein engineering.

Richard Kang, Ph.D. – Chief Operating Officer / Chief Financial Officer

Dr. Richard Kang has served as Chief Operating Officer and Chief Financial Officer since 2015 and 2018, respectively. Dr. Kang joined NeoImmuneTech’s Board of Directors in January 2014. Dr. Kang is an active serial entrepreneur. He has served as Board of Directors and Chief Operating Officer at NeuroBo Pharmaceuticals, Inc. and has served as Board of Directors and Chief Executive Officer at JK BioPharma Solutions, Inc. Prior to diving in Bio/Pharmaceutical industry, he had been achieved scientific publications including Cell and Nature as a scientist in Genetics, Molecular and Cellular Biology and Pathology. Dr. Kang holds B.S. and M.S. from Seoul National University in Korea and Ph.D. from the University of Edinburgh in UK and was a postdoctoral visiting fellow at National Cancer Institute, NIH.

Su Youn Nam, M.D., Ph.D. – Chief Medical Officer / Chief Development Officer

Dr. Nam joined NeoImmuneTech in April 2017 as a Chief Development and Chief Medical Officer. Prior to that, she had led the R&D effort at Yuhan Corporation, Korea. She began her experience in the biopharmaceutical industry in 2004 as the Asia-Pacific Regional Medical Lead in Cardiovascular & Metabolics area based in Singapore, and as Global Medical Director in the Metabolics Franchise of Global Medical Affairs, Princeton, NJ where she developed and executed global medical strategies. Dr. Nam received her M.D. and Ph.D. in Internal Medicine/Endocrinology from the Yonsei University in Seoul, Korea, and went on to be Assistant Professor in Endocrinology at the same institution, following a postdoctoral research at the Karolinska Institute in Stockholm, Sweden.

Jaehan Park – Chief Strategy Officer

Mr. Park joined NeoImmuneTech, Inc. in 2016 as Chief Strategy Officer, in charge of Strategy and Business Development. He has expertise in strategic planning and business development in the bio industry with 13+ years’ experience. Prior to joining NIT, Mr. Park served as Head of Business Development at Genexine. He began his professional career as a business consultant at Accenture, Ltd. Mr. Park received his B.S. degree in Physics from Seoul National University and Master of Engineering degree in Biotechnology from Yonsei University.